Trial reportInternational journal of clinical pharmacy2023
Randomized controlled trial for anesthesia during gastroscopy: interactions between remimazolam and propofol in combination with sufentanil.
Trial report in International journal of clinical pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- The safety and efficacy of remimazolam, ciprofol, and propofol anesthesia in endoscopy: a systematic review and network meta-analysis.BMC anesthesiology · 2025Pooled it
- Effectiveness and safety of remimazolam tosilate versus propofol for sedation in patients undergoing gastrointestinal endoscopy: a randomized controlled trial.International journal of clinical pharmacy · 2024Trial
- Effect of converting from propofol to remimazolam with flumazenil reversal on recovery from anesthesia in outpatients with mental disabilities: a randomized controlled trial.BMC anesthesiology · 2024Trial
- Age‑stratified median effective dose (ED₅₀) of remimazolam besylate for successful gastroscope insertion without body movement in geriatric patients.BMC anesthesiology · 2026Article
- Association between a remimazolam-propofol combination for maintenance of anesthesia and extubation time: a propensity score analysis.JA clinical reports · 2025Article
- Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Remimazolam.European journal of drug metabolism and pharmacokinetics · 2025Review
- A Modified Fiberoptic Endoscopic Evaluation of Swallowing Evaluating Esophageal Dysphagia by a Capsule: A Pilot Study.Dysphagia · 2025Article
- The effective sedative dose of remimazolam for BIS <60 during general anesthesia induction between elderly and non-elderly patients-A randomized controlled trial.Frontiers in pharmacology · 2025Article
- Advances in the Clinical Application of MAC: A Review of Drug Selection, Combination Therapy, and Administration Methods.Drug design, development and therapy · 2025Review
- Pharmacokinetics-Pharmacodynamics Modeling for Evaluating Drug-Drug Interactions in Polypharmacy: Development and Challenges.Clinical pharmacokinetics · 2024Review
- Clinical Application and Research Progress of Remimazolam for Pediatric Patients.Drug design, development and therapy · 2024Review
- Remimazolam in General Anesthesia: A Comprehensive Review of Its Applications and Clinical Efficacy.Drug design, development and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemimazolam is a new short-duration anesthetic currently used for gastroscopy and can be mixed with propofol and potent opioids.
aimThe study aimed to investigate the synergistic interaction between remimazolam and propofol after sufentanil administration and to determine the appropriate dose ratios between remimazolam and propofol.
methodThis study used a randomized controlled design. Patients scheduled for gastrointestinal endoscopy were included and randomized into five groups. The randomized block design was applied at a randomization ratio of 1:1. Patients in each group received sufentanil (0.1 μg/kg) and the calculated doses of remimazolam and propofol. Using the up and down method, the median effective dose (ED
resultsCross-sectional analysis of the isobologram showed a clinically significant synergistic effect between remimazolam and propofol. When 0.016, 0.032, and 0.047 mg/kg of remimazolam were combined with 0.477, 0.221, and 0.131 mg/kg of propofol, the interaction coefficients were 1.04, 1.21, and 1.06, respectively. The dose ratio of remimazolam to propofol was approximately 1:7.
conclusionRemimazolam and propofol have synergistic clinical effects. A strong synergistic effect was observed when the remimazolam and propofol dose ratio was 1:7 (mg/kg). CLINICAL TRIAL: The study protocol was registered at the Chinese Clinical Trial Registry (ChiCTR2100052425).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.